1,961 Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Trillium Asset Management LLC

Trillium Asset Management LLC decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 3.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,144 shares of the pharmaceutical company’s stock after selling 1,961 shares during the period. Vertex Pharmaceuticals comprises approximately 1.0% of Trillium Asset Management LLC’s investment portfolio, making the stock its 24th largest holding. Trillium Asset Management LLC’s holdings in Vertex Pharmaceuticals were worth $30,400,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. MADDEN SECURITIES Corp acquired a new position in Vertex Pharmaceuticals during the third quarter worth $26,000. Meeder Asset Management Inc. purchased a new position in Vertex Pharmaceuticals during the second quarter valued at $26,000. Community Financial Services Group LLC acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at about $26,000. Elevation Wealth Partners LLC grew its position in shares of Vertex Pharmaceuticals by 103.7% in the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 28 shares during the period. Finally, Pingora Partners LLC acquired a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at about $32,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Weiss Ratings cut shares of Vertex Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a research note on Monday, November 9th. UBS Group raised their price target on shares of Vertex Pharmaceuticals from $615.00 to $640.00 and gave the company a “buy” rating in a research note on Tuesday, November 3rd. Scotiabank lifted their price objective on Vertex Pharmaceuticals from $558.00 to $660.00 and gave the stock a “sector outperform” rating in a report on Tuesday, November 3rd. Barclays boosted their price objective on Vertex Pharmaceuticals from $617.00 to $626.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 4th. Finally, Daiwa Securities Group increased their target price on Vertex Pharmaceuticals from $555.00 to $556.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $596.44.

Get Our Latest Research Report on Vertex Pharmaceuticals

Vertex Pharmaceuticals Price Performance

VRTX stock traded down $4.02 during midday trading on Friday, reaching $538.60. The stock had a trading volume of 755,937 shares, compared to its average volume of 1,580,871. The company’s fifty day simple moving average is $522.37 and its 200 day simple moving average is $483.84. The company has a current ratio of 2.34, a quick ratio of 1.89 and a debt-to-equity ratio of 0.17. The company has a market cap of $136.56 billion, a price-to-earnings ratio of 34.66, a price-to-earnings-growth ratio of 2.87 and a beta of 0.28. Vertex Pharmaceuticals Incorporated has a 52-week low of $412.27 and a 52-week high of $568.67.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The business had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same period in the previous year, the company earned $4.80 EPS. Vertex Pharmaceuticals’s quarterly revenue was up 11.8% compared to the same quarter last year. As a group, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

Featured Stories

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.